Delcath Systems Inc. Common Stock (DCTH)

FairStock Score: 47/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses I can understand, with durable competitive advantages, honest accounting, and a price that leaves room for error. Delcath is an interventional oncology company selling HEPZATO KIT for liver cancers. The growth is real: in fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $29.1 million and net income $2.7 million, or $0.07 diluted EPS. For FY2025 ended 2025-12-31, revenue was $85.2 million and net income $2.7 million; a year earlier, FY2024 revenue was $37.2 million with a $26.4 million net loss, and FY2023 revenue was only $2.1 million with a $47.7 million net loss. FairStock labels it a TURNAROUND because it returned to profit after losses within the last three years. That is impressive.

In plain English: Delcath Systems sells a liver-cancer treatment called HEPZATO KIT. Sales have grown quickly and the company is now slightly profitable, but profits are thin and uneven. At $15.32, the stock looks expensive compared with the small earnings and accounting value shown in the data.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer